You are here

Stabilization of Influenza Vaccine by Silica-Coating

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AI126940-01
Agency Tracking Number: R41AI126940
Amount: $224,993.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAID
Solicitation Number: PA15-270
Solicitation Year: 2015
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-08-15
Award End Date (Contract End Date): 2018-07-31
Small Business Information
Portland, OR 97239-1975
United States
DUNS: 079866594
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (503) 317-1086
Business Contact
Phone: (503) 317-1086
Research Institution

The goal of this Phase I STTR grant proposal is to stabilize live attenuated influenza vaccine LAIV using a
temporary silica coating that is removed in vivo In so doing we will establish a broader technology to eliminate
the cold chain required for transport of heat and cold labile vaccines Many vaccines are unstable under
ambient environmental conditions Currently vaccines are either stabilized in liquid formulations and must be
kept between C or are lyophilized stored frozen and then reconstituted just before use Maintaining the
cold chain demands great expense and logistic issues for distribution with the result that an estimated
million children die each year worldwide from vaccine preventable diseases We have developed a proprietary
technology to reversibly inactivate a wide variety of viruses by coating them with silica The coating confers
the viruses with extraordinary tolerance to dessication This coating is completely reversible and dissolves in
vivo rendering the viruses once again effective as vaccines in a preliminary test both silica coated and
uncoated vaccinia virus induced similar T cell mediated immune responses in vivo in a murine model We
hypothesize that we can silica coat live attenuated influenza vaccine and that this coating will stabilize the
vaccine suspension at ambient temperatures eliminating the need for refrigeration or freezing To establish
proof of concept we propose three aims in Phase I Aim Coat and uncoat LAIV with silica Aim Show
that coated LAIV is stabilized in vitro Aim Show that coated LAIV replicates and generates an immune
response in vivo At the conclusion of this Phase I STTR project we will have reached our Milestones
showing that we can coat LAIV and the coating protects the vaccine from inactivation yet still causes
an immune response Thereby we will have established proof of concept for silica coating of vaccines
without loss of immunogenicity and will be poised to launch Phase II in which we will work directly with
vaccine manufacturers and developers to stabilize their vaccines and vaccine candidates develop industrial
scale coating processes show that coated vaccines confer protective immunity and perform toxicity testing to
support regulatory filing Many vaccines are unstable unless they are kept cold but maintaining the cold chain during
shipping and storage is expensive and is subject to failures that render the vaccine ineffective or
unusable We propose here to employ a novel technique to stabilize Live Attenuated Influenza
Vaccine with a reversible silica coating If successful this technique could be employed more
widely on other vaccines to save money and lives by allowing more facile distribution and less

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government